Arrowhead Pharmaceuticals reported fiscal third-quarter 2026 results for the period ended June 30, 2026. Revenue rose to $75.3 million from $27.8 million a year earlier, but the net loss attributable to Arrowhead widened to $194.3 million, or $1.36 per diluted share, from $175.2 million, or $1.26 per share, as research and development and selling, general and administrative expenses increased.
Revenue was $75.3 million for the quarter, compared with $27.8 million in the prior-year quarter.
Net loss attributable to Arrowhead was $194.3 million, or $1.36 per diluted share, versus $175.2 million, or $1.26 per share, a year earlier.
Research and development expense was $198.2 million, up from $162.4 million, and SG&A expense was $47.1 million, up from $30.9 million.
Total cash resources were $1.57 billion at June 30, 2026, compared with $781.5 million at September 30, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Arrowhead Pharmaceuticals's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$829.45M
+23258.2%
$-0.01
—
-0.2%
FY2024
$3.55M
-98.5%
$-5.00
—
-16882.4%
FY2023
$240.74M
-1.0%
$-1.92
—
-85.3%
FY2022
$243.23M
+75.9%
$-1.67
—
-72.4%
FY2021
$138.29M
+57.2%
$-1.36
—
-101.9%
Frequently asked questions
When is Arrowhead Pharmaceuticals's next earnings date?
Arrowhead Pharmaceuticals (ARWR) is scheduled to report on Thursday, November 12, 2026 after the market closes. Analysts expect EPS of $-1.59.
What did Arrowhead Pharmaceuticals earn last quarter?
For the quarter ended Jun 2026, Arrowhead Pharmaceuticals reported diluted EPS of $-1.36 on revenue of $75.25M (+171.0%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.